Oscar Health (OSCR) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Oscar Health (NYSE: OSCR) recently:

• 6/10/2026 – Oscar Health was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $35.00 price target on the stock, up from $30.00.
• 6/6/2026 – Oscar Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/5/2026 – Oscar Health was downgraded by Zacks Research from “strong-buy” to “hold”.
• 6/4/2026 – Oscar Health was given a new $20.00 price target by Wells Fargo & Company. They now have an “equal weight” rating on the stock.
• 6/4/2026 – Oscar Health was upgraded by Wells Fargo & Company from “strong sell” to “hold”. They now have a $20.00 price target on the stock.
• 5/26/2026 – Oscar Health had its price target raised by Barclays PLC from $21.00 to $30.00. They now have an “equal weight” rating on the stock.
• 5/9/2026 – Oscar Health was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 5/7/2026 – Oscar Health had its price target raised by UBS Group AG from $15.00 to $20.00. They now have a “neutral” rating on the stock.
• 5/7/2026 – Oscar Health had its price target raised by Barclays PLC from $18.00 to $21.00. They now have an “equal weight” rating on the stock.
• 5/7/2026 – Oscar Health was upgraded by Zacks Research from “hold” to “strong-buy”.
• 5/7/2026 – Oscar Health had its price target raised by Robert W. Baird from $15.00 to $19.00. They now have a “neutral” rating on the stock.
• 5/5/2026 – Oscar Health is now covered by Wolfe Research. They set a “peer perform” rating on the stock.
• 4/21/2026 – Oscar Health had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 4/20/2026 – Oscar Health was upgraded by Jefferies Financial Group Inc. from “underperform” to “hold”. They now have a $16.00 price target on the stock, up from $10.00.

Insider Activity

In related news, CFO Richard Scott Blackley sold 100,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $23.16, for a total transaction of $2,316,000.00. Following the completion of the transaction, the chief financial officer owned 1,216,660 shares in the company, valued at $28,177,845.60. The trade was a 7.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Janet Liang sold 12,475 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total transaction of $273,701.50. Following the transaction, the insider owned 259,057 shares of the company’s stock, valued at approximately $5,683,710.58. This trade represents a 4.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 189,660 shares of company stock worth $4,283,140 over the last 90 days. 25.11% of the stock is currently owned by insiders.

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.